AA
TVTX icon

Antipodean Advisors’s Travere Therapeutics TVTX Stock Holding History

Antipodean Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-84,000
Closed -$2.79M – 37
2015
Q2 		$2.79M Buy
+84,000
New +$2.3M 0.29% 25

Other funds holding TVTX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return

Antipodean Advisors's TVTX Position: Q3 2015 in Review

Antipodean Advisors sold out of Travere Therapeutics (TVTX) in Q3 2015, closing a stake of 84,000 shares — an estimated $2.79M sold.

Antipodean Advisors first reported a position in TVTX in Q2 2015 and held it in 1 quarter. The position peaked at $2.79M in Q2 2015. 133 funds tracked by Wall St. Rank hold TVTX as of Q3 2015.

  • Antipodean Advisors reported no remaining Travere Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Antipodean Advisors sold 84,000 Travere Therapeutics shares in Q3 2015, an estimated $2.79M.
  • Antipodean Advisors first reported a position in Travere Therapeutics in Q2 2015 and held it in 1 quarter.
  • Antipodean Advisors's Travere Therapeutics position peaked at $2.79M in Q2 2015.
  • 133 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2015.

Based on Antipodean Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.